CA2557615A1 - Treatment of haemorrhagic shock using complement 5a receptor inhibitors - Google Patents

Treatment of haemorrhagic shock using complement 5a receptor inhibitors Download PDF

Info

Publication number
CA2557615A1
CA2557615A1 CA002557615A CA2557615A CA2557615A1 CA 2557615 A1 CA2557615 A1 CA 2557615A1 CA 002557615 A CA002557615 A CA 002557615A CA 2557615 A CA2557615 A CA 2557615A CA 2557615 A1 CA2557615 A1 CA 2557615A1
Authority
CA
Canada
Prior art keywords
side chain
shock
inhibitor
group
haemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002557615A
Other languages
English (en)
French (fr)
Inventor
Denis W. Harkin
Thomas F. Lindsay
Steven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland filed Critical University of Queensland
Publication of CA2557615A1 publication Critical patent/CA2557615A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002557615A 2003-05-15 2004-05-14 Treatment of haemorrhagic shock using complement 5a receptor inhibitors Abandoned CA2557615A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003902354 2003-05-15
AU2003902354A AU2003902354A0 (en) 2003-05-15 2003-05-15 Treatment of haemorrhagic shock
PCT/AU2004/000642 WO2004100975A1 (en) 2003-05-15 2004-05-14 TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS

Publications (1)

Publication Number Publication Date
CA2557615A1 true CA2557615A1 (en) 2004-11-25

Family

ID=31501223

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002557615A Abandoned CA2557615A1 (en) 2003-05-15 2004-05-14 Treatment of haemorrhagic shock using complement 5a receptor inhibitors

Country Status (5)

Country Link
EP (1) EP1635857A1 (enExample)
JP (1) JP2006528208A (enExample)
AU (1) AU2003902354A0 (enExample)
CA (1) CA2557615A1 (enExample)
WO (1) WO2004100975A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP6898229B6 (ja) 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての５－５融合環
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist

Also Published As

Publication number Publication date
JP2006528208A (ja) 2006-12-14
WO2004100975A1 (en) 2004-11-25
EP1635857A1 (en) 2006-03-22
AU2003902354A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
KR19990063958A (ko) 지혈성 디펩티드의 약학 조성물 및 이의 사용방법
US11154587B2 (en) Use of peptides to stimulate the immune system
AU2021202310A1 (en) Compositions and methods for treating acute radiation syndrome
US5498601A (en) Platelet aggregation-inhibiting peptides
US20220160820A1 (en) Modulators of complement activity
WO2004100975A1 (en) TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS
RU2313364C2 (ru) Способы индукции длительного иммунного ответа
WO2009151714A2 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN102946897B (zh) 糖尿病的血管并发症的治疗
US20060276390A1 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
KR100186656B1 (ko) 신규한 펩타이드, 및 전기 펩타이드를 이용하는 혈소판 응집저해제, 체외순환하는 혈액의 혈액응고 저해제, 세포점착저해제, 종양전이 저해제, 수혈용 혈소판 제제의 보호제, 수혈용 혈소판 제제 및 혈소판 제제 팩
WO2015022326A1 (en) Peptides as active agents for treating primary graft dysfunction
AU2004238089A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
KR100266929B1 (ko) 약학적 라이신-함유 폴리펩티드 조성물 및 그의 사용방법
WO2004004551A2 (en) Alpha-melanocyte stimulating hormone peptides protection in organ transplantation
US20100189802A1 (en) Method for treatment of vascular hyperpermeability
AU2018210166A1 (en) Compositions and methods for treating iron overload
US20070054841A1 (en) Method of treatment of systemic injury secondary to burns
US20210228681A1 (en) Compositions and methods for treating glioblastoma
US20260035417A1 (en) Use of an annelid molecule for treating and/or preventing at least one complement-activation associated disease
US20100099602A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
ES2366538T3 (es) Tratamiento de la enfermedad inflamatoria intestinal.
KR0133998B1 (ko) 위장질환 치료용 의약 조성물
WO2011093851A1 (en) Method for treatment of vascular hyperpermeability

Legal Events

Date Code Title Description
FZDE Discontinued